Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica

Annals of Neurology

Volumn 75, Issue 3, 2014, Pages 447-453

  Greco, Raffaella ^a   Bondanza, Attilio ^b   Vago, Luca ^a   Moiola, Lucia ^a   Rossi, Paolo ^a,c   Furlan, Roberto ^a   Martino, Gianvito ^a   Radaelli, Marta ^a   Martinelli, Vittorio ^a   Carbone, Maria Rosaria ^b   Lupo Stanghellini, Maria Teresa ^a   Assanelli, Andrea ^a   Bernardi, Massimo ^a   Corti, Consuelo ^a   Peccatori, Jacopo ^a   Bonini, Chiara ^b   Vezzulli, Paolo ^a   Falini, Andrea ^a,d   Ciceri, Fabio ^a   Comi, Giancarlo ^a,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Experimental Hematology Unit   (France)

^c Neurology Department Hildebrand Hospital   (Switzerland)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; EXPANDED DISABILITY STATUS SCALE; HUMAN; MALE; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REMISSION;

ADULT; AQUAPORIN 4; AUTOANTIBODIES; BONE MARROW; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE SUBSETS; MALE; NEUROMYELITIS OPTICA; TRANSPLANTATION, HOMOLOGOUS;

EID: 84898007710     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24079     Document Type: Article

References (20)

1. Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-234.
2. Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47: 770-790.
3. Marmont AM,. Will hematopoietic stem cell transplantation cure human autoimmune diseases? J Autoimmun 2008; 30: 145-150.
4. Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2005; 35: 869-879.
5. Muraro PA, Douek DC,. Renewing the T cell repertoire to arrest autoimmune aggression. Trends Immunol 2006; 27: 61-67.
6. Mancardi GL, Murialdo A, Rossi P, et al. Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler 2005; 11: 367-371.
7. Van Wijmeersch B, Sprangers B, Rutgeerts O, et al. Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect. Biol Blood Marrow Transplant 2007; 13: 627-637.
8. Herrmann MM, Gaertner S, Stadelmann C, et al. Tolerance induction by bone marrow transplantation in a multiple sclerosis model. Blood 2005; 106: 1875-1883.
9. Daikeler T, Hugle T, Farge D, et al. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant 2009; 44: 27-33.
10. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17: 1019-1032.
11. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
12. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70: 2197-2200.
13. Fazio R, Radaelli M, Furlan R,. Neuromyelitis optica: concepts in evolution. J Neuroimmunol 2011; 231: 100-104.
14. Collongues N, de Seze J,. Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord 2011; 4: 111-121.
15. Barnett MH, Sutton I,. Neuromyelitis optica: not a multiple sclerosis variant. Curr Opin Neurol 2012; 25: 215-220.
16. Kurtzke JF,. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
17. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201: 805-816.
18. Bernardo ME, Piras E, Vacca A, et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 2012; 120: 473-476.
19. Berzins SP, Uldrich AP, Sutherland JS, et al. Thymic regeneration: teaching an old immune system new tricks. Trends Mol Med 2002; 8: 469-476.
20. Goverman JM,. Immune tolerance in multiple sclerosis. Immunol Rev 2011; 241: 228-240.